OMERS ADMINISTRATION Corp Raises Stock Holdings in Edwards Lifesciences Corporation $EW

OMERS ADMINISTRATION Corp lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 22.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 56,160 shares of the medical research company’s stock after acquiring an additional 10,169 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Edwards Lifesciences were worth $4,497,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the 1st quarter valued at $25,000. Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $27,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,577 shares of company stock valued at $3,855,527 in the last three months. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on EW shares. Mizuho increased their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $87.00 to $101.00 in a research note on Friday. Finally, Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $99.55.

Edwards Lifesciences Stock Performance

Shares of EW opened at $83.21 on Tuesday. The firm has a fifty day moving average of $87.74 and a 200-day moving average of $83.86. The company has a market cap of $47.91 billion, a price-to-earnings ratio of 47.82, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.